ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,459.10
1.11%
US Tech 100
18,522.40
1.05%
다우존스 지수
40,589.34
1.64%
Bitcoin
67,895.13
-0.03%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. argenx SE (ARGX)

  7. argenx SE (ARGX) 뉴스

ARGX argenx SE

494.46
8.13 (1.67%)
시간외 거래
최종 업데이트: 06:30:00
15분 지연
기업명 주식 심볼 시장 주식 타입
argenx SE ARGX 나스닥 주식예탁증서 (DR)
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
Upgrade Icon
8.13 1.67% 494.46 06:30:00
개장가 저가 고가 종가 전일 종가
476.04 473.67 495.50 494.46 486.33
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
25/07/202419:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
25/07/202414:00GLOBEargenx Reports Half Year 2024 Financial Results and Provides..
18/07/202414:00GLOBEargenx to Report Half Year 2024 Financial Results and Second..
17/07/202406:22EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17/07/202405:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/07/202413:30GLOBEargenx and Zai Lab Announce Approval of Efgartigimod Alfa..
16/07/202413:15BWZai Lab and argenx Announce Approval of Efgartigimod Alfa..
26/06/202405:30GLOBEargenx Highlights Breadth of Autoimmune Pipeline with New..
22/06/202405:50GLOBEargenx Announces FDA Approval of VYVGART Hytrulo for Chronic..
17/06/202419:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17/06/202414:00GLOBEargenx to unveil its ‘Vision 2030: Taking Breakthrough..
04/06/202414:00GLOBEargenx to Present at Goldman Sachs 45th Annual Global..
09/05/202420:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/05/202414:00GLOBEargenx Reports First Quarter 2024 Financial Results and..
08/05/202419:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/05/202406:30GLOBEargenx announces results of Annual General Meeting of..
07/05/202414:00GLOBEargenx to Present at BofA Securities 2024 Health Care..
02/05/202414:00GLOBEargenx to Report First Quarter 2024 Financial Results and..
16/04/202414:00GLOBEargenx Data Highlight Evidence that VYVGART and VYVGART..
27/03/202415:00GLOBEargenx Advances Clinical Development of Efgartigimod in..
27/03/202405:00GLOBEargenx Announces Annual General Meeting of Shareholders on..
26/03/202415:00GLOBEargenx Announces Approval of VYVGART (efgartigimod alfa) in..
08/03/202420:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/03/202406:01GLOBEargenx Delivers on Promise to Transform Patient Expectations..
01/03/202406:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/02/202415:00GLOBEargenx Reports Full Year 2023 Financial Results and Provides..
26/02/202415:00GLOBEargenx to Present at Upcoming Investor Conferences
22/02/202415:00GLOBEargenx to Report Full Year 2023 Financial Results and Fourth..
20/02/202420:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/02/202415:00GLOBEargenx Announces FDA Acceptance of Supplemental Biologics..
18/01/202420:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/01/202415:00GLOBEargenx Announces Approval of VYVDURA® (efgartigimod alfa and..
08/01/202420:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/01/202415:00GLOBEargenx Highlights 2024 Strategic Priorities
02/01/202415:00GLOBEargenx to Present at 42nd Annual J.P. Morgan Healthcare..
21/12/202302:37DJNArgenx Down Nearly 26%, on Pace for Record Percent Decrease..
20/12/202320:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/12/202315:00GLOBEargenx Reports Topline Results from ADDRESS Study of..
29/11/202301:16DJNArgenx Down Over 10%, On Track for Largest Percent Decrease..
28/11/202321:03DJNArgenx Shares Down After Vyvgart Study Misses Primary..
28/11/202320:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/11/202315:00GLOBEargenx Reports Topline Results from ADVANCE-SC Study of..
17/11/202320:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/11/202321:40GLOBEargenx Announces European Commission Approval of..
02/11/202305:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/11/202315:00GLOBEargenx to Present at Upcoming Investor Conferences
31/10/202322:14EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/10/202315:00GLOBEargenx Reports Third Quarter 2023 Financial Results and..
24/10/202314:00GLOBEargenx to Report Third Quarter 2023 Financial Results and..
28/09/202305:42EDGAR2Form S-8 - Securities to be offered to employees in employee..

최근 히스토리

NASDAQ
ARGX
argenx
BOV
RNEW3M
RENOVA ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유